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Abstract
This article reviews and summarizes chromosomal changes responsible for the initiation and
progression of uroepithelial carcinomas. Characterization of these alterations may lead to a better
understanding of the genetic mechanisms and open the door for molecular markers that can be
used for better diagnosis and prognosis of the disease. Such information might even help in
designing new therapeutic strategies geared towards prevention of tumor recurrences and more
aggressive approach in progression-prone cases.
The revision of 205 cases of uroepithelial carcinomas reported with abnormal karyotypes showed
karyotypic profile characterized by nonrandom chromosomal aberrations varying from one or few
changes in low-grade and early stage tumors to massively rearranged karyotypes in muscle invasive
ones. In general, the karyotypic profile was dominated by losses of chromosomal material seen as
loss of entire chromosome and/or deletions of genetic materials. Rearrangements of chromosome
9 resulting in loss of material from 9p, 9q, or of the entire chromosome were the most frequent
cytogenetic alterations, seen in 45% of the cases. Whereas loss of material from chromosome arms
1p, 8p, and 11p, and gains of chromosome 7, and chromosome arm 1q, and 8q seem to be an early,
but secondary, changes appearing in superficial and well differentiated tumors, the formation of an
isochromosome for 5p and loss of material from 17p are associated with more aggressive tumor
phenotypes. Upper urinary tract TCCs have identical karyotypic profile to that of bladder TCCs,
indicating the same pathogenetic mechanisms are at work in both locales. Intratumor cytogenetic
heterogeneity was not seen except in a few post-radiation uroepithelial carcinomas in which
distinct karyotypic and clonal pattern were characterized by massive intratumor heterogeneity
(cytogenetic polyclonality) with near-diploid clones and simple balanced and/or unbalanced
translocations. In the vast majority of cases strong correlation between the tumors grade/stage and
karyotypic complexity was seen, indicating that progressive accumulation of acquired genetic
alterations is the driving force behind multistep bladder TCC carcinogenesis. Although most of
these cytogenetic alterations have been identified for many years, the molecular consequences and
relevant cancer genes of these alterations have not yet been identified. However, loss of TSG(s)
from chromosome 9 seems to be the primary and important event(s) in uroepithelial
carcinogenesis
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Uroepithelial cancer e.g., cancer of the urinary bladder,
ureter, and renal pelvis, is the 4th and 8th most common
malignant neoplasm in men and the women respectively
[1]. In areas where infestation with Schistosoma haemato-
bium is endemic, uroepithelial cancer is even more com-
mon and accounts for 25% of all cancers in men. The
incidence, the etiologies, and the histology types vary con-
siderably among countries. In Europe and the USA, chem-
icals, including smoking, are the main etiology of
dominant transitional cell carcinoma (TCC) (90%) of the
bladder. The picture is reversed in the Middle East and
Africa, where urinary Schistosoma haematobium is associ-
ated with an increased risk of developing BC, especially of
the SCC type. In these areas BC is the most common can-
cer in men (25% of all cancers) [2].
Uroepithelial cancer is characterized by unique natural
history that is characterized by heterogeneity of the clini-
cal course seen as variation in clinical-course of tumors
[3]. Even tumors of the same pathologic stage, may follow
very different clinical courses. The prognostic markers cur-
rently used are tumor grade, multiplicity, tumor shape,
location, and presence of carcinoma in situ (Cis); however
all are of limited value [4,5]. The difficulties encountered
in predicting the clinical course, especially for superficial
bladder tumors may suggest that TCC has at least two
main subgroups with distinct genetic make-ups and, con-
sequently, clinical behavioral patterns [6]. The natural his-
tory is also characterized by high incidence of recurrence
seen in 70% of the cases after the initial treatment even in
superficial bladder tumors [3,7]. Ureteral and renal pelvis
tumors also have a high risk (40%–75%) of having recur-
rent bladder tumor and 50% of these cases develop metas-
tasis [8]. Of these, 80% remain superficial throughout the
patient's life, whereas 16% to 25% eventually recur as
higher grade and/or stage tumor(s) [9]. The last clinical
characteristics of uroepithelial carcinomas is the multifo-
cal nature of the disease, seen in around 30% of urinary
tract TCC at the time of diagnosis [5]. Although the mech-
anism behind the polychronotopicity of uroepithelial car-
cinomas is settling, since the possibility of new tumor(s)
arising as the result of field cancerization was ruled out by
cytogenetic analysis of synchronous and/or meta-
chronous tumors [10], the heterogeneity of the clinical
course justify the need for the study of prognostic genetic
marker. Such information when made available might
help in the design of new therapeutic strategies geared
toward a more aggressive multimodal treatment approach
in progression-prone cases.
Materials and methods
A total of 205 uroepithelial tumors (188 bladder tumors,
15 ureteral, one renal pelvis and one prostatic urethra
tumor) were obtained from 153 male and 48 female
patients. They were processed for short-term culturing and
chromosomal analysis after staining with Wright stain
according to the standard protocols. All cases revealed
cytogenetic abnormality and all were reported previously
[Appendix 1]. Of these only 3 tumors were SCC, whereas
the remaining were of TCC type. The histopathology
examination revealed superficial disease (Ta-1/GI-II) in
109 tumors and muscle invasion (T2-or more) in 96
tumors. For each case the histology grading, the tumor
staging, and the karyotypic descriptions were reviewed in
order to understand chromosomal changes and cytoge-
netic profile associated with biological parameters of
uroepithelial tumors.
Maps of breakpoints and imbalances
To help identify chromosomal changes in a more compre-
hensive manner, the data were also presented as break-
point and karyotypic imbalance maps (Figures 1 and 2).
In order to report the basic and most representative range
of cytogenetic changes and to avoid cytogenetic noise
brought about by possible ploidy shifts, we included only
2n-4n clones for each tumor in the maps. In case of dupli-
cated aberrations found within a clone or in more than
one related clone, the breakpoints were plotted once only.
If any aberrant chromosome was involved twice in the
same clone or in a related clone, only additional break-
points were considered. When the same chromosome was
involved in both numerical and structural aberrations, we
recorded only the total net imbalance, and if the same
imbalance was found in more than one related clone, it
was recorded only once. If additional gains or losses of the
same chromosome or chromosomal segment were found
in related clones, only the largest imbalance was recorded.
Results
A total of 205 uroepithelial carcinomas have been
reported with chromosomal changes.(Appendix 1). Of
these, 40 (18%) had grossly incomplete karyotypes, 58
(26%) displayed altogether 157 unidentified marker
chromosomes as well as 18 unidentified ring chromo-
somes and a total of 208 uncertain breakpoint, as is evi-
dent from how the karyotypes were written [11].
All chromosomes were involved in numerical and/or
structural aberrations at least once. The most commonly
involved were chromosomes 9 (in 45%) of cases, 1 (in
29%), 11 (in 27%), 8 (in 22%), 7 (in 20%), Y (in 20%),
5 (in 18%), 17 (in 18%), 3 (in 17%), 15 (in 15%), 6 (in
13%), 14 (in 13%), and 18 (in 12%).
A total of 15 unbalanced recurrent chromosomal rear-
rangements were described: del(1)(q21), i(1)(q10),
i(5)(p10), del(6)(q21), i(11)(q10), del(1)(p11),
add(3)(q21), add(5)(q11), del(6)(q13), i(13)(q10),
del(14)(q24), and i(17)(q10).Page 2 of 9
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in the 205 uroepithelial TCC showing structural chromo-
somal abnormalities (Figure 1), with the highest number
of breakpoints (95) seen in chromosome 1 and more than
40 seen in chromosomes 2, 3, 5, 6, 8, 9, 11, and 13. The
chromosome bands most frequently involved were 1p12,
1q12, 2q21, 1q25, 2q27, 5p10, 6q21, 9p10, 9q22, 10q22,
11p15, 11p11 and 13q12 (each involved at least 10
times). The karyotypic imbalances resulting from the
structural and numerical chromosomal aberrations (Fig-
ure 2) were dominated by loss of an entire copy of chro-
mosomes 4, 9, 10, 14, 15, 16, 18, 21, 22, X, and Y, and
gain of entire copy of chromosomes 7, 16, 19, and 20.
Losses of the entire arms or parts of 1p, 5q, 8p, 9p, 11p,
13p, 15p and 17p and gain of 1q, 3q, 5p, 8q, 13q, and 17q
were also common.
Discussion
Although uroepithelial carcinomas are among the most
common malignancies, their karyotypic characteristics
and genetic pathway remain poorly understood. Most of
the reported data are quantitatively limited and lacking
karyotypic precision [11]
Although no specific chromosomal aberration has been
identified for uroepithelial carcinomas, a clearly nonran-
dom pattern of chromosomal changes has emerged, albeit
with considerable karyotypic heterogeneity among cases
ranging from the presence of sole anomalies in early
tumors to very complex karyotypes in advanced ones.
Translocations are rarely seen, at least in early stages, and
seem to play no important role in the initiation of uroep-
ithelial carcinomas. Instead, the cytogenetic profile is
Distribution of 677 breakpoints observed in structural chromosomal aberrations in 205 uroepithelial carcinomasFigure 1
Distribution of 677 breakpoints observed in structural chromosomal aberrations in 205 uroepithelial carcinomas.Page 3 of 9
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especially, losses, the latter indicating that loss of tumor
suppressor gene(s) may be the most crucial event in the
pathogenesis of uroepithelial carcinomas.
The fact that chromatin losses dominated the imbalance
pattern indicates that loss of tumor suppressor gene(s) is
the most important pathogenetic consequence of the
chromosomal aberrations associated with uroepithelial
carcinoma.
Changes involving chromosome 9 [-9, del(9p), del(9q)]
are the most common chromosomal aberrations in
uroepithelial carcinomas. Rearrangements of chromo-
some 9 are seen as the sole change in cases with simple
karyotypes in early and superficial carcinomas but also
persisted in the massively complex karyotypes of
advanced muscle invasive tumors [12]. Besides loss of the
entire chromosome copy, losses of material from either
arms is often seen, which may indicates the presence of at
least one pathogenetically important TSG in each arm
[13,14] (Figures 3 and 4). Loss of chromosome 9 material
had therefore been widely accepted as an early ubiqui-
tous, pathogenetically important and early event in uri-
nary tract transitional cell carcinogenesis [15,16]. Recent
data suggest that 9q abnormalities are more common in
Ta compared with T1 tumors, in which a mixture of aber-
rant 9p and 9q genotypes are seen [17]. These observa-
tions indicate that loss of 9p material may be associated
with the development of tumors with more aggressive
biological behavior or, alternatively, they may be related
to early disease progression [6]. Although several
Karyotypic imbalances caused by numerical and structural aberrations in 205 uroepithelial carcinomasFigure 2
Karyotypic imbalances caused by numerical and structural aberrations in 205 uroepithelial carcinomas. Losses are shown in 
red, gains in blue.Page 4 of 9
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TSC1 in 9q34 have been reported to be homozygously
deleted in superficial TCC of the bladder [18] the crucial
gene-level consequences of these chromosomal aberra-
tions remain unknown.
Trisomy 7 has been frequently described in near-diploid
karyotypes and as the sole chromosomal change in blad-
der and ureteral tumors [19] (Figure 5). The importance of
trisomy 7 as a tumor-associated aberration and its molec-
ular consequence remain controversial since it has been
found repeatedly also in some unquestionably nonneo-
plastic lesions [20]. However, the important molecular
consequences of trisomy 7 may be an increased number of
alleles for the epidermal growth factor (EGF) receptor
gene.
In addition to chromosomes 9 and 7, chromosomes 1, 8,
and 11 seemed to be preferentially involved and were
found to be rearranged in superficial tumors. Alterations
involving chromosome 1 had been seen in 35% of the
investigated BC cases [11]. The alterations are diverse and
include deletions, translocations, duplications, and iso-
chromosome formations. However, regardless of the type
of changes, the most common consequences of the
changes in chromosome 1 were gain of 1q material and
loss of 1p material. Changes involving chromosome 1 are
rarely if ever seen as the sole aberration but nevertheless
may form part of relatively simple karyotypes. Support for
the view that changes of chromosome 1 are secondary in
BC tumorigenesis also comes from molecular cytogenetic
investigations showing that gain of 1q material is more
frequent in pT1 than in pTa tumors [21]. Regardless of
when they occur, the molecular consequences and
biological significance of these changes in uroepithelial
carcinomas remain uncertain, although some investiga-
tors suggest that they may be implicated in tumor progres-
sion and in vitro immortalization of human cells [22].
Aberrations involving chromosome 8 usually resulting in
loss of material from the short arm, have been repeatedly
detected in urinary tract tumors. Losses from 8p and gain
of 8q were the dominant net result in, almost all, changes
affecting this chromosome. Although often found in sim-
ple karyotypes of low-grade tumors, the aberrations
involving chromosomes 1, 8 and/or 11 were never the
sole change, but typically accompanied by chromosome 9
rearrangements [11]. Similar aberrations occur frequently
Representative karyotype from a well differentiated transitional cell carcinoma of the bladderFigure 3
Representative karyotype from a well differentiated transitional cell carcinoma of the bladder. The arrowhead indicates the 
breakpoint in a deleted chromosome 9 {46,XY,del(9)(p11)}.Page 5 of 9
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Representative karyotype from a well differentiated transitional cell carcinoma of the bladder. The arrowhead indicates the 
breakpoint in a deleted chromosome 9 {46,XY,del(9)(q12q22)}.
Representative karyotype from a well differentiated transitional cell carcinoma of the bladderFigure 5
Representative karyotype from a well differentiated transitional cell carcinoma of the bladder. The chromosome indicated by 
"mar" represents unidentified marker, "r" represents ring chromosome. Arrowheads indicate breakpoints.Page 6 of 9
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lung[23]. Studies of patients with non-muscle-invasive
bladder cancers have shown more frequent loss of 8p in
minimally invasive (pT1) tumors than in non-invasive
(pTa) ones [24]. These findings are consistent with the
view that loss of a putative TSG on 8p plays important role
in the progression and tumor invasion in BC.
Several cytogenetic studies have revealed nonrandom
involvement of chromosome 11 in BC, mostly leading to
loss of genetic material from 11p [11]. Additional evi-
dence to the same effect has come from CGH analy-
ses[25]. The frequency of 11p loss may be higher in pT1
than in pTa tumors, and even higher in pT2-4b tumors
[26]. In contrast, some FISH studies using centromeric
probes have shown an increased copy number of chromo-
some 11[27]. However, these studies did not assess the
tumors' ploidy level and the seemingly increased copy
number may therefore have reflected general polyploidi-
zation. Loss of 11p therefore appears to be an early but
secondary change, associated with tumor progression. The
putative TSG on 11p lost through the chromosomal rear-
rangements remain unknown.
Chromosomal changes associated with aggressive 
biological tumor behavior
The formation of an isochromosome for 5p, i(5)(p10),
leading to net gain of material from the short arm of chro-
mosome 5 has been reported in bladder TCCs, making it
the single most common recurrent structural chromo-
somal abnormality in Uroepithelial tumors [11]. In most
cytogenetic reports the aberration was associated with
aggressive tumor phenotypes, muscle-invasive and poorly
differentiated tumors. Considering the fact that this
marker has not been consistently linked to any other
malignancy and that it is seldom seen in association with
rearrangements of chromosome 17, it appears to charac-
terize a subgroup of advanced TCC of the bladder arising
via a unique pathogenetic pathway. A strong correlation
between chromosome 5 involvement and tumor grade
and stage was shown in several studies [6,28].
Rearrangement of chromosome 17 resulting in loss of
material from the short arm is rarely seen in superficial
BC, but is common in more advanced and aggressive
tumors. The molecular target of 17p material loss could be
the TP53 gene, which resides at 17p12, and is known as
the most generally important tumor suppressor gene in
human neoplasia. Cytogenetic analyses revealed involve-
ment of 17p in less than 10% of the analyzed tumors, and
molecular genetic studies have shown LOH in up to 42%
of the tumors. While cytogenetic data probably underesti-
mate 17p involvement. However, this finding indicates
that most deletions of 17p are submicroscopic and thus
cannot be detected using conventional cytogenetic tech-
nique. On the other hand, several FISH analyses using
centromeric probes have revealed frequent chromosome
17 copy-gain in bladder carcinomas of high grade and
stage. Such apparent gains of whole chromosome copies
in FISH analyses may reflect polyploidization in advanced
tumors rather than a specific role of chromosome 17.
Although rearrangement of chromosome 17 resulting in
loss of material from the short arm was seen frequently in
high-grade, muscle-invasive tumors, loss of 17p material
is not restricted only to advanced TCC [12]. The loss of
17p material in some superficial tumors fits the prognos-
tic heterogeneity seen even in superficial BC in which
some tumors take a more aggressive clinical course. For
these ones it has been suggested that early loss of 17p,
combined with mutational inactivation of the TP53 allele
on the other chromosome 17, could be responsible for the
aggressive behavior seen in 16–25% of superficial BCs.
Rearrangement of chromosome 3 resulting in loss of
material from the short arm had been seen in 44% of the
reported BC with abnormal karyotypes, usually in
advanced tumors with complex karyotypes [29]. Deletion
of 3p is also frequent in other carcinomas such as renal
cell cancer, breast cancer, and small cell lung cancer [11].
Although many potential target genes are located on 3p,
the crucial molecular-level consequence of these chromo-
somal aberrations in BC carcinogenesis remains
unknown.
Aberrations involving chromosome 13 are known to
occur in muscle invasive tumors and often result in net
loss of material from the long arm [11]. LOH studies seem
to be more informative than cytogenetic studies in this
prospect as LOH at the RB locus in band 13q14 was seen
in 90% of muscle invasive tumors.
Loss of the Y chromosome is common in bladder tumors
of male patients. It has been reported in all stages and
even as the sole change in several reports [30]. In contrast,
bladder tumors obtained from female patients do not
reveal the same incidence of X chromosome loss. FISH
studies have shown that loss of the Y is infrequent in nor-
mal urothelial cells obtained from healthy males [31].
This observation does not exclude, however, the possibil-
ity that loss of chromosome Y in cultured cells could
reflect changes in stromal elements, in particular since-Y
has been demonstrated in non-neoplastic disease lesions
of several tissues and organs such as kidney, bone mar-
row, and brain [32,33]. In conclusion, one cannot be cer-
tain that loss of the Y chromosome really signifies a
pathogenetically important event in neoplastic cells.
Correlation between karyotype and tumor grade and stage
Strong correlation was seen between the grade/stage of the
tumors and the karyotypic profile. Most superficial andPage 7 of 9
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diploid and exhibited simple karyotypes (5 or fewer chro-
mosomal changes) (Figures 3, 4, 5). A progressive increase
in the number of chromosome aberrations with tumor
grade and/or stage was evident in most large reported
series, with TaG1 tumors showing less abnormal karyo-
types than did those that were T1G2, which, in their turn,
were less abnormal than T2G3 tumors. This is in agree-
ment with the view that the uroepithelial carcinomas fol-
low the multistep carcinogenesis and that their clinical
progression is steered by the synergistic effect of accumu-
lated genetic alterations.
Upper urinary tract carcinomas (UUTC)
Very limited information is available on cytogenetics of
UUTC; only 16 cases with abnormal karyotype, have been
published [34,35]. Because of the great similarities
between upper urinary tract carcinomas (UUTC) and
bladder TCC with regard to etiology, histology, and natu-
ral disease history, one would assume that the tumori-
genic mechanisms, including the karyotypic profile, are
more or less identical.
Loss of material from chromosome 9 was seen in most
informative UUTC [12]. The ubiquity of chromosome 9
involvement thus seems to be no less pronounced in
UUTC than BC; this is in agreement with the view that this
is an early and crucial event in the genesis of nearly all uri-
nary tract TCC, regardless of their site and stage. The high
frequency of chromosome 9 involvement in upper uri-
nary tract transitional cell carcinogenesis makes this a log-
ical target for a possible genetic marker to be used in the
follow-up of patients with such tumors, something that
would be particularly useful considering how frequent
downstream disease spreading is in these patients.
Post-radiation uroepithelial carcinomas
Post-radiation tumors or second-primary radiation-
induced cancers have distinct clinical and cytogenetic
characteristics. These tumors develop in an irradiated field
and should have a different histological type from that of
the primary tumors. Usually they are infiltrative and of
high grade at the time of diagnosis. Only 2 cases of post-
radiation uroepithelial carcinoma with cytogenetics
abnormality have been reported [35,36]. The karyotypic
profile in both cases revealed near-diploid, karyotypically
abnormal clones characterized by rather simple balanced
and/or unbalanced translocations in each tumor. The
intratumor karyotypic heterogeneity seen in these cases
indicates massive polyclonality in contrast to the cytoge-
netic monoclonality consistently demonstrated in urinary
tract TCC. This reflects the likelihood of the previous radi-
ation carcinogenic effect and illustrating that post-radia-
tion urinary tract tumors are distinct from other urinary
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